PDCO Stock Holds $31.33 on NASDAQ as Medical Distributor Stabilizes

Patterson Companies, Inc. (PDCO) trades at $31.33 on NASDAQ with flat intraday movement as of April 21, 2026. The medical distributor serves dentists, veterinarians, and animal health professionals across the United States, United Kingdom, and Canada. PDCO stock has climbed 21.62% over the past year, recovering from its $19.45 low. With a market cap of $2.77 billion and 88.5 million shares outstanding, PDCO stock reflects steady positioning in the healthcare distribution sector. The company operates three core segments: Dental, Animal Health, and Corporate services.

PDCO Stock Valuation and Price Action

PDCO stock trades near its 50-day moving average of $31.11, showing consolidation after recent gains. The stock sits $0.46 below its 52-week high of $31.79 but remains $11.88 above its 52-week low. Volume surged to 6.77 million shares, more than 4.6 times the average daily volume of 1.45 million, signaling renewed investor interest. The P/E ratio stands at 20.48, suggesting moderate valuation relative to earnings. PDCO stock’s price-to-sales ratio of 0.85 indicates reasonable value compared to revenue generation. The stock’s 200-day moving average sits at $26.03, confirming an uptrend over the medium term.

Financial Metrics and Profitability Analysis

Patterson Companies reports earnings per share of $1.53 with a net profit margin of 1.79%, reflecting tight operational efficiency typical of distribution businesses. Revenue per share reaches $36.77, demonstrating solid top-line generation. The company maintains a current ratio of 1.41, indicating adequate short-term liquidity to cover obligations. Return on equity stands at 5.94%, while return on assets reaches 2.05%, showing modest but positive capital efficiency. Debt-to-equity ratio of 0.58 suggests balanced leverage. However, free cash flow per share turns negative at -$5.47, a concern requiring monitoring. Operating cash flow also runs negative at -$5.10 per share, indicating working capital pressures in the distribution model.

Meyka AI Rating and Analyst Consensus

Meyka AI rates PDCO with a grade of B+, reflecting neutral positioning with mixed signals across key metrics. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating incorporates strong DCF, ROE, and ROA scores balanced against weaker debt and valuation metrics. Analyst consensus shows 1 Buy rating with no holds, sells, or strong recommendations, suggesting cautious optimism. These grades are not guaranteed and we are not financial advisors. The company’s next earnings announcement is scheduled for June 16, 2025, providing an upcoming catalyst for PDCO stock movement.

Market Sentiment and Trading Activity

Trading activity in PDCO stock reflects moderate engagement with relative volume at 4.66 times normal levels. The stock’s intraday range remains tight at $31.33, suggesting consolidation rather than directional conviction. Liquidation pressure appears minimal given the stable price action and elevated volume. The Keltner Channel bands converge at $31.33, indicating low volatility and equilibrium pricing. Money Flow Index at 50.00 shows neutral momentum without overbought or oversold conditions. Relative Vigor Index at 50.00 confirms balanced buying and selling pressure. This technical setup suggests PDCO stock may be positioning for a directional move once catalysts emerge.

Growth Prospects and Dividend Income

PDCO stock offers a dividend yield of 1.66% with an annual payout of $0.52 per share, providing income for patient investors. The payout ratio of 79% indicates management confidence in cash generation despite negative free cash flow. Revenue growth remains modest at 1.50% year-over-year, reflecting mature market dynamics in dental and animal health distribution. Five-year revenue growth per share reaches 17.55%, showing long-term resilience. Net income declined 10.42% year-over-year, pressuring earnings momentum. Three-year net income growth per share stands at 22.57%, suggesting recovery potential. Track PDCO on Meyka for real-time updates on dividend announcements and earnings revisions.

Risks and Forward Outlook

PDCO stock faces headwinds from negative operating cash flow and declining net income trends. The company’s high inventory turnover of 2.92 times and extended cash conversion cycle of 87 days create working capital management challenges. Debt growth of 21.48% year-over-year raises leverage concerns if cash flow doesn’t improve. Healthcare distribution remains competitive with pricing pressure from larger consolidators. However, PDCO’s diversified revenue streams across dental and animal health provide defensive characteristics. The company’s 147-year history and established customer relationships offer stability. Management’s focus on practice optimization software and value-added services may drive future margin expansion.

Final Thoughts

PDCO stock trades at $31.33 on NASDAQ with a B+ rating from Meyka AI, reflecting balanced risk-reward dynamics in the medical distribution sector. The stock’s year-to-date gain of 1.72% and 12-month advance of 21.62% demonstrate resilience despite near-term profitability challenges. Patterson Companies’ diversified business model across dental and animal health segments provides revenue stability, though negative free cash flow and declining net income warrant attention. The 1.66% dividend yield appeals to income-focused investors, while the modest P/E of 20.48 offers reasonable valuation entry points. Upcoming earnings in June 2025 will be critical for assessing management’s progress on cash flow improvement and margin expansion. Investors should monitor PDCO stock for signs of operational turnaround before committing significant capital. The stock’s consolidation near technical support suggests patience may reward disciplined buyers.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.